Mercer Global Advisors
PLX icon

Mercer Global Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Mercer Global Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Buy
+8,639
New +$18.3K ﹤0.01% 4819

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Mercer Global Advisors's PLX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 8,639 shares worth $20.1K. The stake represents ﹤0.01% of the portfolio and ranks #4819 among its holdings.

85 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Mercer Global Advisors held 8,639 shares of Protalix BioTherapeutics worth $20.1K as of Q2 2026.
  • Protalix BioTherapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4819 holding.
  • 85 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.